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Gelatinases produced by stimulated peripheral blood monocytes were detected by substrate zymography and were compared with those derived 
from tumor cells. Stimulated monocytes were found to produce an 85 kDa gelatinase which co-migrated upon electrophoretic separation and cross- 
reacted in immunoprecipitat.ion experiments with a phorbol ester inducible metalloprotease from human tumor cells. The intact natural gelatinase 
(85 kDa), a high molecular weight and complexed gelatinase as well as a proteolytic fragment (25 kDa) were purified by substrate- and antibody 
affinity chromatography techniques. Aminoterminal sequence analysis showed that natural monocyte gelatinase occurs as a truncated form of tumor 
cell gelatinase/type IV collagenase. Furthermore, peripheral blood monocytes were found to also produce a tissue inhibitor of metalloproteases 
(TIMP). TIMP was co-purified with gelatinase on gelatin sepharose and identified by microsequencing. The balanced and regulated production 
of gelatinase and TIMP might be important in monocyte migration and tissue remodeling. 
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1. INTRODUCTION 
Human white blood cells are a rich source of pro- 
teinases such as plasminogen activators, elastase, col- 
lagenase, proteoglycanase and type IV col- 
lagenase/gelatinase [l-8]. The secreted enzymatic ac- 
tivity is balanced by the paracrine or autocrine co- 
production of specific enzyme inhibitors, e.g. 
plasminogen activator inhibitors (PAIs), tissue in- 
hibitor of metalloproteinases (TIMP) [9-l 11. Regula- 
tion of secreted proteinases is also achieved by activa- 
tion of the proenzymes [ 123. Furthermore, localised 
proteolysis is believed to play a key role in the control 
of extracellular matrix degradation [ 13,141. Localisa- 
tion of such proteolysis can be achieved by the presence 
of cellular binding sites for specific proteinases [15]. 
The proteases, their inhibitors and their binding sites 
are under the genetic control of local, often paracrine 
factors, e.g. cytokines 19,161. Thus, chemotactic factors 
can influence the production of proteases and facilitate 
the directional migration of normal leukocytes [17]. 
The migration of tumor cells in invasion and metastasis 
is believed to be controlled by similar mechanisms 
[18,19]. 
Mctalloproteases arc primarily associated with the 
rcmodclling of extracellular matrix molecules (col- 
lagens, proteoglycans, gelatins) and most studied in 
bone and cartilage tissues [20,21], in tumor cells [22,23] 
and also in neutrophilic granulocytes [24], Hcrc WC 
C’~r~r.r/lc,rr/clrrtcr nddrrss: Ci. Opdcnakkcr, Hcga lnrtitutc for blcdical 
Rcsc;~~ch, Utrivcrrity of tcuvc~t, ~lilrdcrhrocdcrrrtrnnl IO, B-?OOO 
Lcuvcn. Belgium. 
describe for the first time the purification to 
homogeneity of natural monocyte gelatinase as well as 
one of its inhibitors. Amino acid sequence analysis 
shows that the monocytic enzyme is a truncated form of 
tumor cell-derived gelatinase. 
2. MATERIALS AND METHODS 
2.1. Reagenrs 
Phorbol l2-my&ate 13-acetate and gela!in were from Sigma, St. 
Louis, MO, USA. Polyriboinosinic* polyribocytidylic acid (PIG) was 
purchased from P-L Biochemicals, Milwaukee, WI, USA. Sodium 
dodecyl sulphate and ovalbumin (5 times cristallised) were from Ser- 
va, Heidelberg. Germany. IL-Ipwas purified from human buffy coat 
supernatants as described [25]. Concanavalin A (Con A) was from 
Calbiochem, San Diego, CA, USA and endotoxir. from E. co/i 
(01 11 .B4) was from Difco, Detroit, MI, USA. 
2.2. Isoluliorl, cd/we and irlducIion of cells 
liuman Malavu cells [26] were grown in stationary culture flasks 
(Falcon Plastics, Oxnard, CA, USA) in Eagle’s minimum csscntial 
medium v ith Earle’s salts (EMEM) (Gibco, Paisley, Scotland), SUP- 
plemented with 10% (v/v) fetal calf serum. Human mononuclear cells 
from hcparinized human peripheral blood from single or multiple 
donors (Belgian Red Cross, Blood Transfusion Centers of Leuvcn 
and Amwcrp) were purified by removal of crythrocytcs (hydroxyethyl 
starch acdimcntntiou) and of ncutrophils (Ficoll/sodium mctrizoatc 
ccntrifugation) as previously dcsrribcd 1271. From the total 
mottonuclcar cell fraction monocytc cultures were obtained by 
udhcrcncc to plastic iu serum-free EMEM (90 min, 37’C) and cxten- 
sivc washing. For the induclion of gclatinascs, 24 multi-well plate 
cultures (Nun-c, Koskildc, Dcnmork) wcrc treated with diffcrcnt in- 
ducers tmd cell culture supcrnat;lms were harvcstcd after the indicated 
time intcrrals. 
2.3. Drlrrtintr q/ ~clatirrrrw nc/ivil,v h,v ;,wrojyaf~lty 
Gclatinasc activity in cell culture supcrniltants aud COIUIII~ frac- 
tions wits dctcrmiucd by sodium dodccyl sulphn~c/polyacryta~~~idc gel 
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electrophoresis (SDS-PAGE) zymography according to a modifica- 
tion of the method of Heussen and Dowdle [24,28]. 
Gelatinase activity was quantified by computerised image analysis 
through two-dimensional scanning densitometry, and gelatinase ac- 
tivity was expressed as the scanning area under the curves, which is an 
integration ratio that takes into account both brightness and width of 
the substrate lysis zone relative to that of a positive control [17]. 
2.4. Purijkation of monocyte gelatinme and amino acid sequence 
nnalysis 
For the production of peripheral blood monocyte gelatinase, about 
10” mononuclear cells from pooled human buffy coats (equivalent to 
100 liters of human blood) were treated for 48 h with 2~g/ml of 
Con A and 2 pg/ml endotoxin in serum-free culture medium. After 
48 h incubation at 37°C. cell supernatants (I .8 liters) were collected 
and filtered (Whatman paper, 3MM, Whatman. Maidstone, England 
and 0.45 micron filter, Sterivex-HV, Millipore, Bedford, MA, USA, 
sequentially). Crude material was purified by substrate-affinity 
chromatography on gelatin sepharose [17] and antibody-affinity 
chromatography. To verify that the protein A-purified I&is, used for 
antibody-affinity chromatography, recognised both :he 65 and the 
SS-kDa gelatinases, all fractions of the protein A affinity 
chromatography were tested with a constant amount of a gelatinase 
laboratory standard by immunoprecipitation analysis as described 
below. 
After gelatin sepharose affinity chromatography, bound enzyme 
was recovered with an elution buffer containing 50 mM Tris-HCI, pH 
7.6. IO mM EDTA, 0.02% NaNI, 0.010/o Tween 20, I M NaCl and 
5% (v/v) DMSO. Four fractions (12 ml each) contained more than 
98% of the eluted gelatinolytic activity. These were pooled and ap- 
plied to the antibody-affinity column equilibrated with PBS. The col- 
umn was eluted with 0.1 M citrate, 0.5 M N&I, 0.01% (v/v) Tween 
20, pH 2. Four fractions (5 ml each) containing approximately 50% 
of the eluted gelatinolytic activity were supplemented with IoOpg 
ovalbumin in 5 ml of bidistilled water and extensively dialysed against 
bidistilled water. The addition of ovalbumin enhanced protein 
recoveries after dialysis and did not interfere with subsequent 
aminoterminal sequence analysis since ovalbumin is NH:-terminally 
blocked. After dialysis, the volume was reduced to 2 ml by freezc- 
drying in siliconised glass tubes and the remaining material again 
dialysed against bidistilled water. After concentration by lyophilisa- 
tion, the sample (50,uI) was separated by SDS-PAGE in a 10% gel 
with a 4% stacking gel. The proteins in the gel were electrotransferred 
in a semi-dry blotting apparatus 1291 for 4 h at 200 mA onto a Pro- 
blott membrane (Applied Biosystems, Foster City, CA) following the 
recommendations of the manufacturers. The membrane was then 
stained wirh Coomassic blue R-250. Fragments of the filter showing 
the stained protein bands were excised and the aminoterminal se- 
qucnces of the corresponding proteins were determined in a modified 
version of the sequence cycle (BLOTT-I) on an automated gas-phase 
sequencer (Applied Biosystems, model 477 A with on-line analyscr 
model I20 A). The adapted cycle for use in pulsed liquid chemistry 
yields higher sequencing efficiency with Pro-blott membranes in the 
absence of polybrenc. 
2.5. Irnrrtunoprecipitation of~elotitwses 
Gclatinolytic activity was immunoprecipitatcd with a polyclonal 
antiserum against the 67- and 85.kDa gelatinascs from Malavu cells 
[ 171. Briefly, gelatinascs were reacted with the antibody and the im- 
munc complcxcs ;~recipitatcd by binding IO protein A on prctrcatcd 
Staphylococcus b,. IDI cells. Alter cxtcnsivc washing of the 
precipitates, the complcscd tnolcculcs wcrc dissocintcd with SDS and 
scparatcd by SDS-PAGE. Rcnctivatcd pclatinosc activity was tlcter- 
mined by zymoyraphy as dcscribcd 1261. 
3. HESULTS 
3. 1. Cottzprisorz of gelalirzases produced by lzzrttzatz 
trzotzocy~es urzd 1utzzor cells 
Chfl~~llt c~ltufes of humnn Malavu cells or 
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adherent peripheral blood monocytes were stimulated 
in serum-free medium for 24 h. Culture fluids of un- 
treated and treated cells were tested for the production 
of gelatinases by a substrate conversion assay. Fig. 1A 
shows these zymographic analyses. The Malavu cells 
spontaneously secreted high levels of a 65kDa 
gelatinase. These cells could be stimulated by phorbol 
ester to produce a 85-kDa gelatinase. Human 
monocytes treated with IL-l,& or the double-stranded 
RNA PIC, secreted exclusively a 8%kDa gelatinase. 
This cytokine-induced gelatinase from monocytes 
resembles the phorbol ester-induced gelatinase from 
human tumor cells as shown by co-migration on SDS- 
PAGE as well as by immunoprecipitation experiments 
(Fig. 1B). The polyclonal antiserum immunoprecipi- 
tated all forms of tumor cell gelatinase, whereas the pre- 
immune serum did not react with any of these. Further- 
more, the immunoprecipitated amounts of gelatinase 
were sufficient to yield enzymatic activity in 
zymographic assays. 
The immune antiserum reproducibly precipitated an 
active enzyme from monocyte culture fluids with an ap- 
parent molecular weight of 85 kDa (Fig. 1B). When 
larger volumes of culture fluid were used it became ap- 
parent that monocytes aIso produce lesser amounts of 
another gelatinase that had a molecular weight of 
65 kDa. Most probably this is the homologue of tumor 
cell gelatinase with an apparent molecular weight of 
67 kDa (Fig. 1B). Similarly, the human myelomono- 
cytic cell line, THP-1, when stimulated with IL-I,& or 
Fig. I, Relationship of IL-l-induced monocytic gclatinosc with the 
85-k&1 8clatinasc from phorbol cstcr-stimulated tumo:’ cells. (A) 
Zynrogrnphic analysis. Samples of II.-l,&stimulatcd (100 U/ml) OI 
poly(rl)a poly(rC)-trcotcd (PIG, 100 &ml) humn ~no~~ocy~ca (III) 
il11d phorbol cstcr-trcatcd (PMA, IQ0 ng/ml) hlalnvu ceils (Ii) wcrc 
subjcctcd to zymogrophy for migration analysis. (B) II~I~NII~O- 
prccipilntion of monocytic gclatinasc by a polyclonal anliscrum 
dircrtcd against Malavu cell gclatinascs. Symbols arc as in panel A. 
Prc. inclisittcs llic bymogratrhic min!ysis after precipitation with 
prcimmunc and inr. with iinmunc SCI’UIII. 
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Fig. 2. Purification of monocytc gelatinase. (A) Substrate affinity chromatography on gelatin sepharose. Conditioned medium from stimulated 
monocytes was reacted with gelatin, coupled to sepharose. To prevent digestion of the substrate, the gelatinase was inhibited with EDTA. After 
extensive washing of the affinity resin, the bound enzyme was eluted and protein content as well as enzyme activity determined on all fractions. 
The: insets show ~hc zymcgraphic analyses. (B) Affinity chromatography on IgG column. Monocyte gclatinasc was purified by immunoadsorption 
to a polyclonal antibody against tumor cell-derived gelatinase. The bound enzyme was cluted at pH 2, neutraliscd and concentrated. Legends as 
in A. (C) Staining analysis of reduced monocytc gelatinase. Approximately 5 pg of purified gelatinasc, supplcmentcd with 5 /rg of ovalbumin were 
scpa z!-:l b:: gel ?lcctrophoresis and stained with Coomnssic blue. Arrows indicate the position of the 85 kDa, 65 kDa, ovalbumin (OV) and TIMP 
rcspectivcly. 
phorbol ester, produced a gelatinase of approximately 
90 kDa. This myelomonocytic gelatinase also reacted 
with the antibody directed against Malavu-gelatinase in
immuno-precipitation experiments. However, THP-1 
cells did not product the 65 kDa gclatinasc (data not 
shown). 
3 -2. Plrt*iJcotiott of tttorlocyte geiutirtnse atld i&n- 
tificntiotr of seqltettce nnalysi.s 
Mononuclear cells from a large pool of buffy coats 
were xtimulatcd for 48 h with Con A and cndotoxin in 
serum-free medium. The supernatant fluids were sub- 
jected to substrate affinity chromatography on gelatin 
sepharose (Fig. 2A). All activity was recovered and the 
purification factor was 300-fold. The eluate from the 
substrate column was further processed by antibody- 
affinity chromatography (Fig. 2B) using the antibody 
against Malavu gelatinase. The purification factor was 
2.8 and the recovery 75Vo. Staining analysis of the 
purified sample showed the presence of 3 protein bands 
at 85, 65 and 25-30 kDa respectively (Fig. 2C). The 
85.kDa protein migrated to the same position as the ac- 
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Table I 
NHz-terminal sequence analysis of natural monocyte gelatinase and comparison with tumor-derived gelatinase” 
June 1991 
Reduced natural monocyte gelatinase (85 kDa) Unreduced natural monocyte gelatinase 
(~100 kDa complex) 
LFPGDLRT. . (m,40%)b 
LVLFPGDL. . (m, 60%) 
APRQRQSTLVLFPGDLRT.. (t) 
LFPG-LR-NLTD. . (30070)~ 
LVLFPGDLR-NL.. (70%) 
Peripheral blood monocytes (m) were stimulated with Con A (2 &ml) and E. co/i endotoxin (2 /cg/ml) for 48 h. 
Gelatinases from culture fluids were purified by affinity chromatography on gelatin-sepharose and specific antibody, 
followed by SDS-PAGE. After electroblotting to a solid support the transferred proteins were processed on a gas-phase 
microsequencer. The comparison of reduced monocytic (m) gelatinase and tumor cell-derived gelatinase (t) from 
fibrosarcoma cells [30] is shown. The sequence of monocyte gelatinase was at the 2.5 pmol level. 
070 indicates relative amount of the variant form. 
tive enzyme (determined by’ zymography analysis). 
After extensive dialysis and concentration, 55 ,ug of 
antibody-purified material was denatured and further 
separated by SDS-PAGE. The proteins in the gel were 
then electrotransferred to a solid support and stained 
with Coomassie blue. Parts from the blotting mem- 
brane containing the stainable bands were excised and 
the corresponding polypeptides were sequenced. The 
amino acid sequences of the 85-kDa gelatinase as well as 
the percentage occurrence of each sequence are sum- 
marised in Table I. The experimentally determined se- 
quences from monocytic gelatinase could be aligned 
with those of fibrosarcoma type IV collagenase [30]. 
Comparison of secreted monocytic with tumor-derived 
gelatinase shows that the former lacks at least 8 
NHz-terminal amino acid residues. In addition, at least 
two NHt-terminal variants were present in the 
monocyte-derived preparations, the most abundant 
(60%) species being two residues longer than the other 
species. Except for the truncation, the microsequencing 
analysis together with the serological crossreactivity in- 
dicates identity between the core polypeptide of the 
monocytic natural gelatinase and that of tumor cells. 
In order to verify the amino acid sequence, a sample 
was processed by electroblotting transfer without prior 
reduction and denaturing. It is known that this pro- 
cedure yields higher molecular weight complexes [5]. A 
sample so-obtained was processed as above and was 
found to yield the sequence shown in Table I. Amino- 
terminal truncation as well as relative abundancies were 
comparable to those obtained with the reduced sample. 
3.3. Purification and identification of a tissue inhibitor 
of metalloproteinases 
When the afore- mentioned 25-30 kDa protein, co- 
purified with gelatinase from monocytes, was visualised 
after electroblotting and the corresponding protein(s) 
analysed, two sequences were obtained (Table IIA). A 
weak signal was observed in the 3 pmol range cor- 
responding perfectly to those of previous analyses of in- 
tact gelatinase. Therefore, the latter represents a frag- 
ment of intact gelatinase. This indicates that the gelatin- 
binding domain of monocyte gelatinase (and its 
fragments) are located in the amino terminal third of 
the intact molecule. 
A second sequence signal was obtained in the 
15 pmol range. This sequence, shown in Table IIB, 
could be aligned with that of purified erythroid- 
potentiating activity of T-lymphoblasts [31] and with 
that of the tissue inhibitor of metalloproteinases 
(TIMP) [32]. Thus, monocytes produce, in parallel with 
gelatinase, an inhibitor of this mctalloproteinase. 
Table II 
NHz-terminal scqucnce analysis of 25 kDa polypcptide? 
Unreduced 25 kDa gclatinasc fragment 
(3 pm01 signal) 
Unreduced 25 kDa monocytc TIMP 
(15 pm01 signal) 
L -LFPGDL-T. a (30%)b 
LFPGDL -TNLTD. , (70%) 
5 10 IS 20 25 
-T-VPPHPQTAF -NSDLVI -A-F -GTPE 
ATCVPPH-QTAI’CNSDLVI RAKFVG-I (EpO) 
CTCVPPHPQTAFCNSDLVI RAKFVGTPE (TIMI’) 
a Pooled huffy coot mononuclear cells wcrc stimulated for 48 h with Con A and cndotoxin and UIC sulturc fluids jbcrc proccsscd as 
in Fig. 2. A protein band of 2%30 kUa was cxciscd and the amino tcrminnl reslducs scqucnccd. Tlrc left panel shows the rclntivc 
prsscncc of the gelatlnitse fragments. III the right pmcl the monocyte flhll’ scqucncc was romparcd with the amltio acid SCC~ILWCC 
of human crythroid-potcnriating factor (EPO) [JIJ and M0 T-Iymphoblartic tirsuc inhibitor of Inctnlloprotcinnlcs (Tlhll’) (32). 
h O’ ,o indicates rclativc ittllouttt or tlrc wktnt form. 
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4. DISCUSSION 
The present study describes the detection of 
gelatinase induced and secreted by stimulated human 
peripheral blood monocytes. This gelatinase has a 
molecular weight of approximately 85 kDa as assayed 
by SDS-PAGE using both zymography and staining 
analysis. The monocytic gelatinase is inducible by the 
cytokine IL-I and by double-stranded RNA. The 
monocytic gelatinase was identified as the possible 
homologue of a phorbol ester-inducible gelatinase from 
human tumor cells by the following criteria: (a) co- 
migration on SDS-PAGE, (b) binding with and activity 
against the gelatin substrate, and (c) serological rela- 
tionship as determined by immunoprecipitation and 
binding experiments. Compared to other cell types such 
as human diploid fibroblasts, melanoma, osteosarcoma 
and hepatoma-derived ccl1 lines [26], which all secrete 
several different gelatinolytic enzymes, monocytes from 
peripheral blood preparations eem to produce mainly 
the 8S-kDa type. Only after concentration of monocyte 
gelatinase by immunoprecipitation, an additional 
6%kDa species was observed on zymography. 
Monocyte gelatinase preparations, concentrated by 
chromatographic purification also showed the presence 
of the 65-kDa enzyme on zymography (data not 
shown). Characterisation i  terms of structural analysis 
and functional properties of the 65-kDa species is im- 
paired by the low yields obtained. 
All experiments were performed under serum-free 
conditions. This was found to avoid ‘spontaneous’ pro- 
duction of gelatinase by monocyt~s. Serum-free culture 
conditions were also necessary because of the presence 
of intrinsic gelatinases in all sera tested. 
By the subsequent use of affinity chronlatography on 
gelatin substrate and on antibody directed against 
purified tumor cell gelatinase, two major proteins were 
co-purified: gelatinase and a tissue inhibitor of 
metalloproteinases. Most likely TIMP was indirectly 
bound to the affinity resins via complex formation with 
gelatinase. Previous studies have already established the 
presence and regulation of TIMP in monocytes [lo,1 I]. 
Gelatinases of 67-72 kDa and of 90 kDa have been 
isolated from bronchial avage or alveolar macrophages 
[7,33]. Upregulation in alveolar macrophages of a 
90-kDa gelatinase by Escherichia coli endotoxin, was 
recently described f33]. Similarly, EGF and IL-l have 
been reported to induce type IV collagenase/gelatinase 
in tumor cells [30]. 
gelatinase/type IV collagenase previously isolated from 
tumor cells [30]. Furthermore, the monocytic gelatinase 
core enzyme is identical to that from neutrophils [ 171. It 
remains to be determined which enzymes are involved 
in this truncation process and whether such biochemical 
differences can be exploited to discriminate between 
normal (leukocytic) and pathological (tumoral) cell 
migration. 
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